MONJUVI IS A MONOCLONAL ANTIBODY THAT TARGETS CD19 ANTIGENS1
MONJUVI (tafasitamab-cxix) is an Fc-modified monoclonal antibody that binds to CD19 antigen expressed on the surface of pre-B and mature B lymphocytes and in several B-cell malignancies, including DLBCL
Upon binding to CD19, tafasitamab-cxix mediates B-cell lysis through:
Immune-effector mechanisms, including
- Antibody-dependent cellular cytotoxicity (ADCC)
- Antibody-dependent cellular phagocytosis (ADCP)
In studies conducted in vitro in DLBCL tumor cells, tafasitamab-cxix, in combination with lenalidomide, resulted in increased ADCC activity compared to tafasitamab-cxix or lenalidomide alone
MOA=mechanism of action; Fc=fragment crystallizable; DLBCL=diffuse large B-cell lymphoma.